FDA issues temporary compounding policies to prevent neonatal starter parenteral nutrition shortages and maintain access for premature and critically ill newborns.
Written By: Mansi Nakum, PharmD
Reviewed By: Pharmacally Editorial Team
The FDA has issued temporary regulatory and enforcement policies to help prevent a supply disruption of neonatal starter parenteral nutrition (PN), an essential intravenous source of early nutrition for premature and critically ill newborns who cannot receive adequate nutrition enterally.
The U.S. Food and Drug Administration issued the guidance for immediate implementation after receiving reports of potential serious supply disruptions linked to the market exit of the predominant source of certain neonatal starter PN products. The agency said there are currently no FDA-approved starter PN drug products for neonates, increasing the clinical importance of maintaining compounded supply.
Essential Early Nutrition for Premature Infants
Starter PN consists of pre-mixed intravenous solutions administered to newborns immediately after birth. The formulations provide early nutrition, including dextrose and amino acids, with some formulations also containing calcium. Patient-specific PN can be prepared separately when required.
The FDA’s intervention reflects a specific supply vulnerability: neonatal starter PN remains clinically important, but its compounded status means hospitals must rely on specialized pharmacy and outsourcing capacity rather than FDA-approved neonatal starter products.
Temporary Flexibility for 503A and 503B Compounders
The guidance provides temporary flexibility for both state-licensed pharmacies and federal facilities that are not registered as outsourcing facilities under Section 503A, and FDA-registered outsourcing facilities operating under Section 503B. The policies remain in effect for 180 days after publication, through March 8, 2027, although FDA may extend, modify or withdraw them as supply conditions change.
For eligible 503A compounders, FDA generally does not intend to take regulatory action when certain neonatal starter PN products are supplied to hospitals without a patient-specific prescription. The products must appear on FDA’s eligible list, carry specified beyond-use dates, be single-use and free of antimicrobial preservatives, and meet other statutory requirements. State pharmacy authorities must also be aware of the compounding activity and not object.
FDA Defines Eligible Formulations and Stability Limits
Appendix A identifies 20 eligible neonatal starter PN formulations, all supplied in 250-mL bags. The formulations contain pediatric-specific amino acids at concentrations ranging from 2% to 6%, with 5% or 10% dextrose and specified combinations of calcium gluconate and heparin.
For aseptically processed neonatal starter PN, the default beyond-use date is 30 hours at controlled room temperature (20°C to 25°C) and nine days when refrigerated at 2°C to 8°C. FDA notes that shorter dating may be necessary when scientific evidence indicates stability could be compromised by formulation or storage factors.
For outsourcing facilities, FDA is also providing temporary enforcement discretion around certain bulk-substance restrictions and stability-testing and expiration-date requirements. Facilities must initiate limited stability testing when aggregate production is expected to exceed 5,000 units and begin container-closure integrity testing with the first batch.
FDA Balances Access with Compounding Risks
The agency emphasized that compounded drugs are not FDA-approved and therefore do not undergo FDA premarket review for safety, effectiveness or quality. The temporary policies reflect the absence of approved neonatal starter PN products and the immediate need to preserve treatment options.
Acting FDA Commissioner Kyle Diamantas said the agency is using available regulatory tools to prevent critical supply-chain gaps from threatening patient care. Michael Davis, M.D., Ph.D., acting director of the Center for Drug Evaluation and Research, highlighted the importance of starter PN for newborns who require nutrition soon after birth.
Supply Monitoring Continues
The FDA will continue monitoring neonatal starter PN supply and demand and will consider further action if necessary. The immediate goal is to maintain hospital access while alternative suppliers increase capacity and longer-term solutions emerge.
The policy illustrates how regulatory flexibility can be used to address a specialized drug-supply vulnerability while retaining safeguards around sterility, formulation, stability and neonatal safety.
Reference
FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products | FDA
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Products for Neonates
About the Writer
Mansi Nakum (Linkedin) is a Pharm.D professional with a strong foundation in clinical pharmacy, evidence-based healthcare writing, and clinical data interpretation.
She has published work on Brugada syndrome and has a keen interest in guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization.
As a healthcare writer, she focuses on translating clinical evidence into clear, accurate, and clinically relevant content, while continuously developing her expertise in evolving pharmacy practice.